Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Fludarabine Phosphate in Beta-Thalassemia: NCT04776850 Clinical Landscape Report 2026
16 October 2026
NCT04776850 clinical landscape for Beta-Thalassemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Eptacog alfa biosimilar (Aryogen) in Hemophilia B: NCT04789954 Clinical Landscape Report 2026
16 October 2026
NCT04789954 clinical landscape for Hemophilia B: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Vitamin E Nicotinicate in Metabolic Dysfunction Associated Steatohepatitis: NCT04801849 Clinical Landscape Report 2026
16 October 2026
NCT04801849 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
SNP-630 in Metabolic Dysfunction Associated Steatohepatitis: NCT04808154 Clinical Landscape Report 2026
16 October 2026
NCT04808154 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
Vamifeport hydrochloride in Anemia, Sickle Cell: NCT04817670 Clinical Landscape Report 2026
16 October 2026
NCT04817670 clinical landscape for Anemia, Sickle Cell: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Efgartigimod/Hyaluronidase in Myasthenia Gravis: NCT04818671 Clinical Landscape Report 2026
16 October 2026
NCT04818671 clinical landscape for Myasthenia Gravis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
HEC-88473 in Metabolic Dysfunction Associated Steatohepatitis: NCT04829123 Clinical Landscape Report 2026
16 October 2026
NCT04829123 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
Plerixafor in Anemia, Sickle Cell: NCT04817345 Clinical Landscape Report 2026
16 October 2026
NCT04817345 clinical landscape for Anemia, Sickle Cell: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Trimetazidine Hydrochloride in Amyotrophic Lateral Sclerosis: NL-OMON52162 Clinical Landscape Report 2026
16 October 2026
NL-OMON52162 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Semaglutide (Novo Nordisk) in Metabolic Dysfunction Associated Steatohepatitis: NCT04822181 Clinical Landscape Report 2026
16 October 2026
NCT04822181 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
Efgartigimod Alfa in Myasthenia Gravis: NCT04833894 Clinical Landscape Report 2026
16 October 2026
NCT04833894 clinical landscape for Myasthenia Gravis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Estradiol in Metabolic Dysfunction Associated Steatohepatitis: NCT04833140 Clinical Landscape Report 2026
16 October 2026
NCT04833140 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…